[177Lu]Lu-DOTATATE治疗新诊断晚期胃肠胰神经内分泌肿瘤的成本效益:基于NETTER-2试验结果的分析
基于NETTER-2试验的分区生存模型显示,[177Lu]Lu-DOTATATE一线治疗2级或3级、高分化、晚期胃肠胰神经内分泌肿瘤,在36个月试验期内增量成本效益比为66,761美元/质量调整生命年,在20年终生分析中优于奥曲肽长效释放剂。概率敏感性分析中64%的蒙特卡洛迭代显示其最具成本效益。
要点
- NETTER-2试验中[177Lu]Lu-DOTATATE组中位无进展生存期22.8个月,奥曲肽长效释放剂组8.5个月。
- 试验期内[177Lu]Lu-DOTATATE增量质量调整生命年0.13,增量成本8,931美元,增量成本效益比66,761美元/质量调整生命年。
- 终生分析中[177Lu]Lu-DOTATATE优于奥曲肽长效释放剂,但增量成本效益比受疾病进展后接受[177Lu]Lu-DOTATATE治疗的患者比例及周期数影响。
核心结论
- [177Lu]Lu-DOTATATE作为2级或3级、高分化、晚期胃肠胰神经内分泌肿瘤的一线治疗具有成本效益。
研究设计与样本
- 建立分区生存模型,模拟试验期36个月及20年终生时限,每组无进展生存期和治疗方案来自NETTER-2试验,总生存期、健康状态效用值及不良事件效用值和成本来自文献,治疗成本来自美国联邦医疗保险和医疗补助服务中心,支付意愿阈值设为每质量调整生命年100,000美元。
主要发现
- 试验期内[177Lu]Lu-DOTATATE增量质量调整生命年为0.13,增量成本为8,931美元,增量成本效益比为66,761美元/质量调整生命年。
- 终生分析中[177Lu]Lu-DOTATATE优于奥曲肽长效释放剂治疗。
- 确定性敏感性分析显示增量成本效益比受疾病进展后接受[177Lu]Lu-DOTATATE治疗的患者比例及进展后接受周期数的强烈影响。
- 采用10,000次迭代的蒙特卡洛模拟进行概率敏感性分析,[177Lu]Lu-DOTATATE在试验期内64%的迭代中为最具成本效益的策略。
关键数值与推荐
- NETTER-2试验中[177Lu]Lu-DOTATATE组中位无进展生存期22.8个月,奥曲肽长效释放剂组8.5个月,两组不良事件和生活质量指标相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recently published results of the NETTER-2 trial suggest the use of [177Lu]Lu-DOTATATE as a new standard of care in first-line therapy of patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic neuroendocrine tumors. The NETTER-2 trial found superior median progression-free survival (22.8 mo vs. 8.5 mo) and similar adverse events and quality-of-life measures in patients treated with [177Lu]Lu-DOTATATE compared with octreotide long-acting release (LAR) alone. As [177Lu]Lu-DOTATATE therapy is associated with higher costs, we compared the cost-effectiveness of [177Lu]Lu-DOTATATE with that of octreotide LAR in this setting. Methods: A partitioned survival model was established for the trial duration of 36 mo as well as a lifetime horizon of 20 y. Progression-free survival and treatment regimens for each patient group were derived from the NETTER-2 trial. Information on overall survival as well as utilities for health states and utilities and costs of adverse events were obtained from the literature. Information on treatment costs was obtained from the Centers for Medicare and Medicaid Services. The willingness-to-pay threshold was set to $100,000 per quality-adjusted life-year (QALY). Results: [177Lu]Lu-DOTATATE was cost-effective during the trial duration, with an incremental QALY of 0.13 at a slightly higher cost ($8,931), leading to an incremental cost-effectiveness ratio of $66,761/QALY. For the lifetime analysis, [177Lu]Lu-DOTATATE dominated treatment with octreotide LAR. However, deterministic sensitivity analysis revealed that the incremental cost-effectiveness ratio was strongly influenced by the percentage of patients treated with [177Lu]Lu-DOTATATE after disease progression as well as number of cycles of [177Lu]Lu-DOTATATE they received after progression. In the probabilistic sensitivity analysis using Monte Carlo simulation with 10,000 iterations, [177Lu]Lu-DOTATATE proved to be the most cost-effective strategy for 64% of Monte Carlo iterations over the trial duration. Conclusion: [177Lu]Lu-DOTATATE is cost-effective as a first-line treatment for patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic neuroendocrine tumors.
引用
- Holzgreve A, Unterrainer LM, Tiling M, et al. Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trial. J Nucl Med. 2025. PMID: 40473457. doi:10.2967/jnumed.124.269416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。